The visual science of a first-in-class treatment in Homozygous Familial Hypercholesterolemia (HoFH).
This excerpt is taken from our 3D animation work for a biopharmaceutical company that developed an FDA-approved orphan drug, aimed at treating the rare genetic disease homozygous familial hypercholesterolemia (HoFH).
This video explores the activity within the body of a person affected with HoFH — explaining the normal and abnormal functions of LDL-C.
Deliverables
3D animations
Multiple Language Videos
3D Illustrations - online, banner & brochure
Client
Aegerion Pharmaceuticals
Brand
Juxtapid (USA) & Lojuxta (EU)
Familial hypercholesterolemia (FH), an autosomal codominant disease, is characterized by high levels of LDL cholesterol and a high incidence of coronary artery disease (CAD).
Homozygous Familial Hypercholesterolemia, or HoFH, is a rare genetic lipid disorder usually caused by defects in the low-density lipoprotein, or LDL, receptor genes, inherited from both parents, resulting in impaired or total loss of function in the LDL receptor.
Senior Director Business Development & US Marketing, Rare Disease, Aegerion Pharmaceuticals, Massachusetts, USA
Suite 6, Claremont House,
22-24, Claremont Rd.,
Surbiton, Surrey,
KT6 4QU, UK
